Michael Finney

Board Chair

2023

Member Board of Directors

2007

Interim Chief Executive Officer

2024 - 2024

I've served on the Board of Directors since 2007, became Chair in 2023, and Interim CEO in January 2024. Previously, I served as CEO for over two years, July 2009 to October 2011. Vaxart is a game-changing company with its technology for oral vaccination, and has an excellent team.

CEO

2009 - 2011

Having served on the board since 2007, in 2009 I came in as acting CEO and ended up staying over 2 years. In this time, we closed a $12 million Series B, completed preclinical work, ran a Phase I clinical trial, and hired a permanent CEO.

Board Chair

2014

Director

2019

Enabling single-cell genomics for solid tissues

Board Chair

2019

Commercializing technology from the Collins lab at UC Berkeley

Managing Director

2004

Director

2016

Reagent systems for DNA sequencing

Director

1998

Board Chair

2005

Board Chair, December 2015-present

Director and Permanent Member

1999

Formerly named G Corp, TGP is a non-profit corporation that is responsible for, among other things, the AGBT Genomics meeting. The meeting has been held every February since 2000. It provides an opportunity for academics and commercial companies in the field of genomics to exchange the latest advances.

Member

2006